Background: Previous studies have measured cerebral blood flow (CBF) with DSC-MRI using an "early time points" (ET) method based on microsphere theory. Purpose: To develop and assess a new ET method for absolute CBF estimation using low-dose high-temporal (LDHT) T1W-DCE-MRI. Study Type: Retrospective cohort study. Subjects: Seven patients with sporadic vestibular schwannoma (VS) who underwent test-retest imaging; one patient with glioblastoma multiforme (GBM) imaged pretreatment; and 12 neurofibromatosis type 2 (NF2) patients undergoing bevacizumab treatment, imaged pre-and 90 days posttreatment. Field Strength/Sequence: LDHT-DCE-MRI was performed at 1.5 and 3.0T, using 3D spoiled gradient echo with phase cycling. DSC-MRI performed in one patient, using 3D echo-shifted multi-shot echo-planar imaging (PRESTO) at 3T. Assessment: Through Monte Carlo simulations, CBF estimation using three newly developed average contrast agent concentration (AC) -based methods (ACrPK, ACrMG, ACcomb), was compared against conventional maximum gradient (MG) approaches, at varying Rician noise levels. Reproducibility and applicability of the ACcomb method was assessed in our sporadic-VS/GBM/NF2 patient cohort, respectively. Statistical Tests: Reproducibility was measured using test-retest coefficient of variation (CoV). Pre-and posttreatment CBF values were compared using paired t-test with Bonferroni correction. Results: Monte Carlo stimulations demonstrated that AC-based methods, particularly ACcomb, offered superior accuracy to conventional MG approaches. Overall test-retest CoV using the ACcomb method was 5.76 in normalappearing white matter (NAWM). The new ACcomb method produced gray matter/white matter CBF estimates in the NF2 patient cohort of 55.9 6 13.9/25.8 6 3.5 on day 0; compared with 155.6 6 17.2/128.4 6 29.1 for the classical MG method. There was a moderate (10% using ACcomb and ACrPK) increase in CBF of NAWM 90 days post therapy (P 5 0.03 and 0.005). Data Conclusion: Our new AC-based method of CBF estimation offers excellent reproducibility, and displays more accuracy in both Monte Carlo analysis and clinical data application, than conventional MG-based approaches. Level of Evidence: 1 Technical Efficacy: Stage 4
T he microsphere method is a classic technique for blood flow quantification, based on the principle that injected labeled particles, which are too big to fit through the capillaries, are delivered to each tissue element in proportion to the local blood flow, and remain trapped there for subsequent counting. While the classic microsphere method is restricted to animal studies, the microsphere model [1] [2] [3] has become the basis for blood flow quantification in both computed tomography (CT), [3] [4] [5] and perfusion MRI. [6] [7] [8] [9] The maximum gradient (MG) method for calculation of cerebral blood flow (CBF) is based on the microsphere model and has been widely applied in perfusion CT. 3, 10 Recently, Kwong et al 7, 11, 12 proposed a technique using the early data points of the contrast agent (CA) bolus for relative CBF (rCBF) calculation with dynamic susceptibility contrast (DSC) MRI. They used measurement from early time points before the gadolinium-based contrast agent (GBCA) has left the tissue, i.e., the time window which meets the microsphere prerequisite. They named the region of the time course curve that meets the requirements of the microsphere model the "early time points window (ETW)" and the analysis technique the "early time points" (ET) method. They proposed that as long as the microsphere prerequisite is satisfied, different ways of manipulating the early rising bolus concentration time course would theoretically yield the same rCBF result, but that one method could prove superior to another under specific noise conditions, and that measurement of absolute blood flow could be achieved with sampling of arterial blood from appropriate arteries. 7, 11, 12 The MG method has, however, not been broadly accepted in T1-weighted (T1W) dynamic contrast enhanced (DCE) MRI evaluation of CBF. 13 There are two main reasons for this: First, the use of the MG method in DCE-MRI data requires that the microsphere prerequisite is met 7 which depends on various factors, including: contrast bolus volume, injection rate and the patient's cardiac output. 10 Second, the MG method requires good enhancement-tonoise ratio (ENR, maximal signal change divided by the standard deviation (SD) of the baseline of the DCE-MRI), which may not always be met in early time-point DCE MRI images used to calculate perfusion. The aim of the current study was to, therefore, develop and assess a new methodology for absolute CBF estimation which uses data derived from a low-dose whole brain 3D coverage T1W DCE MRI acquisition, and is based on the microsphere and ET strategies.
Materials and Methods

Patients
We retrospectively analyzed MRI data from twenty patients, which had been prospectively collected for a previous study using the same T1W DCE MRI protocol. Twelve patients with type 2 neurofibromatosis (NF2), seven patients with sporadic vestibular schwannomas (VS), and one patient with histologically proven glioblastoma multiforme (GBM) were recruited into the study. Ethical approval was in place for the study (NHS Health Research Authority; NRES committee North West 13/NW/0131) and all participants had previously consented for later data analysis of their MRI data. Amongst the 12 NF2 patient cohort there were 21 VS and 11 meningiomas. All 12 patients with NF2 were undergoing treatment with the anti-vascular endothelial growth factor antibody, bevacizumab, and underwent imaging on two occasions: pretreatment (day 0) and 3 months (day 90) following treatment. The seven patients with sporadic VS cohort were imaged on two separate occasions 4 days apart.
MRI
The 12 Patients with NF2 and seven patients with sporadic VS were imaged on a 1.5T scanner (Philips Achieva, Best, Netherlands) using an eight-channel head coil. The patient with a GBM was imaged on a 3.0T scanner (Philips Achieva, 3.0TX).
The following scanning protocols were used: 1) Higher spatial resolution morphological MRI, e.g., high spatial resolution nonenhanced (C-) 3D (Fig. 1a) . A low dose (fixed volume of 3 mL, 0.02 mmol/kg depending on body weight) of macrocyclic GBCA (gadoterate meglumine; Dotarem, Geurbet, Roissy, France) was administered by power injector as an intravenous bolus at a rate of 3 mL/s, followed by a chaser of 20 mL of 0.9% saline administered at the same rate. This LDHT acquisition was then followed by a Full GBCA Dose (0.1 mmol/kg), High-Spatial resolution (matrix size of 240 3 240 3 70) acquisition (FDHS) DCE MRI. As the name of ICR-DICE indicates, a large acquisition volume covering the whole brain is used to eliminate unsaturated flowing spins enter the imaging slab, which can cause undesirable signal enhancement and generate image artifacts. To obtain satisfactory elimination of in-flow artifacts, it is paramount important that (i) the volume coverage of 3D slab is large enough to incorporate the top of the brain, the circle of Willis and the terminations of the internal carotid arteries bilaterally (Fig.  1b) ; (ii) The read gradient of the 3D slab is orientated in parallel to the vessels for the maximum saturation of the out slab upstream.
3) For the GBM patient, following the T1W-DCE MRI acquisition, a dynamic susceptibility contrast enhancement imaging (DSC) series was undertaken, using a 3D echo-shifted multishot echo-planar imaging (3D PRESTO). 15 The PRESTO series used scan parameters of repetition time/echo time/flip angle (TR/TE/flip angle) of 20 ms/26.5 ms/10 8. The contrast bolus administered for the T1W-DCE MRI acquisitions was used as the preload for leakage correction, and a third injection of 0.1 mmol/kg of Dotarem followed by a saline flush was administered at the 5th dynamic frame of the 3D PRESTO-DSC. The DSC has an image matrix of 128 3 128 3 30 and Dt of 1.5 s.
Image Coregistration and Segmentation SPM 16 was used for image coregistration and segmentation of the MRI data into gray matter (GM), white matter (WM), and cerebrospinal fluid (CSF). Three probability maps representing GM, WM, and CSF, segmented from the 3D T1W images, were realigned and re-sliced to the space of the 3D individual volumes of the DCE-MRI of the subject. WM and GM masks were generated using a probability cutoff of 0.975, and these masks were then used for subsequent quantitative analysis. Figure 1b shows the segmented GM, WM, and tumor mask overlaid on the aligned last frame of the 3D LDHT and FDHS.
Measurement of Vascular Input Function
Estimation of absolute CBF requires identification of a suitable arterial input function (AIF), and for practical purposes, a good approximation may be achieved by measuring the input function in the superior sagittal sinus (SSS). 3, 17 Our vascular input function (VIF) measurement method for the T1W LDHT data has been previously described and uses a semi-automatic extraction method, to identify voxels within the SSS that display maximum enhancement during the first pass of the CA bolus. 18 To investigate variations in the shape of VIFs from individually measured C b (t) curves, we retrospectively inspected VIFs from all previous LDHT T1W DCE MRI studies performed in our laboratory that used the same injection protocol. In total, 55 VIFs from 55 visits of 36 patients with NF2 (n 5 20), sporadic VS (n 5 7), and GBM (n 5 9) were analyzed. All participants had consented for later retrospective analysis of their data. We examined variations in the VIF to identify the range in the number of measurement points that can be identified in the early time points window. Data from the T2*W DSC acquisition was processed using the commercially available software tool (MIStar, Apollo Medical Imaging, Melbourne, Australia), which incorporates an automated AIF detection algorithm. This algorithm performs pixelwise calculation of time of bolus arrival (TOA), height, width, and area under curve (AUC) of the DR2* signal, and identifies the AIF as the cluster of pixels which show early arrival, large AUC, high peak height and narrow peak width.
Microsphere Model
A prerequisite for the application of the microsphere theory is "sufficient organ retention." 3 In fact, for a time period less than the minimum intravascular transit time, any indicator behaves like a microsphere, in that no indicator that has arrived in an organ will have yet left it. During this time, the organ "collects" counts, i.e., performs a "biological" integration of the arterial counts. "Mathematical" integration of the arterial counts, i.e., a running sum of the frame-by-frame counts, therefore, generates a curve which has the same shape as the organ curve. 2 Mathematically, the microsphere model can be written as:
where the tissue GBCA concentration, C t (t), is equal to the amount of GBCA delivered to 1 mL of tissue by time t, f is the perfusion term (usually expressed as mL min
is the arterial blood concentration (input function). Then, according to the fundamental theorem of calculus, we have:
and max dC t ðtÞ dt 5f Á max C b ðtÞ :
Eq. [3] suggests that the maximum gradient of the upslope of the first-pass C t (t) is reached at the same time as the regional arterial peak under the microsphere prerequisite:
where t MG and t AIF_peak are the time to the maximum gradient of C t (t) and the time to the peak of AIF, respectively. The MG method for blood flow derivation is then expressed as:
New T1W-ET Methods for Absolute CBF Estimation
The new T1W-ET methods are based on the following two hypotheses: (i) With a low-dose compact bolus, the whole upslope segment before the first pass peak of the tissue concentration-time curves can be taken as the early time window (ETW), and the working data range for the CBF measurement.
(ii) When the effects of noise are considerable, an averaged concentration (AC) -based method, especially when applied on data points located in a segment with higher ENR, is superior to a MG-based method.
To assess the validity of our low-dose T1W DCE MRI protocol for CBF evaluation using the microsphere model, i.e., whether Eq. [1] does hold true for our data, we tested whether the integrated input curve (INT aif ) could be scaled so that it paralleled (or aligned after time shifting) the rising bolus time course of the tissue uptake curve, and if the required scaling factor was within the expected range of the cerebral blood flow (f) for the type of the tissue tested.
The first step of the T1W-ET methods is to identify the first pass peak point of the tissue concentration-time curve, which is the point of maximum enhancement within the 30-s time period following the TOA of the global AIF. The two consecutive data points which display the greatest difference in tissue enhancement within the time segment between the AIF bolus arrival and the first pass peak point, are then found. Five different ways of manipulating the rising bolus concentration time course were compared for absolute CBF evaluation: (i) The classical maximum gradient (MGclassical) method -the two consecutive data points which display the greatest difference in tissue enhancement on the rising bolus time course are identified. The maximum gradient is calculated as (DC t (t)) max /Dt, and used in Eq. [5] to determine CBF.
(ii) The upslope method (the slope method) -the two data points, i and i11, displaying the greatest difference in enhancement are identified and the slope over these two points and two adjacent points [i-1, i, i11, i12] is estimated by linear regression. This slope is then used as the numerator in Eq. [5] for calculating CBF.
The next two methods use the running average of three consecutive data points as the value of C t (t) in Eq. [1] for CBF evaluation. Both methods choose a reference time point (t ref ) other than the TOA, and identify data points located on the upper part of the rising bolus time course (a segment with higher ENR). (iii) AC referencing t MG (the ACrMG method), where t MG 5 (t i 1 t i11 )/2. The running average of three data points [i11, i12, i13] was used as the value of C t (t), therefore, t 5 t i12 5 t MG 1 1.5Á(Dt) 5 t AIF_peak 1 1.5Á(Dt) in Eq. [1] . The value of t AIF_peak was found from the gamma variant fit of the C b (t). (iv) AC referencing t peak (the ACrPK method), where t peak was the tissue peak time. If the time point for the tissue peak was i peak , the running average of three data points [i peak -1, i peak -2, i peak -3] was used as the value of C t (t). For convenience, we used t 5 t AIF_peak 1 1.5Á(Dt) as the upper time limit in integration of AIF, as same as in the ACrMG method. (v) Finally, based on the results from Monte Carlo error analysis of the above four methods, we developed a new method for calculation of the AC. The new method takes the average of the CBF values obtained from the ACrMG and ACrPK methods. We called the combined method the ACcomb method.
We denoted the absolute CBF estimated using the five methods as T1W-CBF ET which comprises CBF ACrMG , CBF ACrPK , CBF ACcomb , CBF MGclassical , and CBF slope , respectively.
Monte Carlo Simulation for Error Analysis
Monte Carlo simulation was used to investigate the effects of noise on the CBF values estimated with the five T1W-ET methods. The
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WM and GM GBCA concentration curves were simulated based on the microsphere model and the hypothesis that the ETW (i.e., the working data range for the CBF measurement) is the whole upslope segment before the first pass peak of the tissue concentration-time curves.
The synthesized WM and GM CA concentration curves (see below), with "true" CBF WM 5 25 mL/min/100 mL and "true" CBF GM 5 60 mL/min/100 mL, respectively, were converted back into signal intensity (SI) -time curves based on the in vivo mean baseline SI, the precontrast T1 relaxation time (T 10 ), and a literature value of longitudinal relaxivity (4.39 mM -1 s -1 ). 19 The generated SI-time courses were sampled with a temporal resolution of 1.0-s, and Rician white noise with noise level ( 5 SD/mean baseline signal) of 1%, 2%, 3%, 4%, and 5%, respectively, was added to the simulated SI-time curves. Absolute CBF values were calculated using the synthetic data sets to produce the so-called "measured" values with the five estimation methods, respectively. Percent deviations (PD) of the "measured" values from the "true" values were calculated as: PD 5 (measured -true)/trueÁ100%. A total of 20,000 repetitions were performed for each method to produce mean and SD of PD for each CBF estimates.
In Vivo Data Processing
T1W-CBF ET images were calculated for the 12 NF2 patients, the 7 sporadic VS patients, and for the 1 patient with a GBM. For the GBM patient, maps of T2*W-CBF and T2*W-CBV were generated from the DSC MRI using MIStar and the singular value decomposition (SVD) deconvolution method of Ostergaard. 20 Previous authors have attempted to use model free deconvolution to analyze T1W DCE data. 21 We, therefore, also analyzed the LDHT DCE-MRI data from our GBM patient using a model free SVD deconvolution approach and compared these derived values with values obtained using the T1W-CBF ET and T2*W-CBF approaches.
We also carried out a tracer kinetic analysis on the T1W-DCE MRI data using the extended Tofts model (ETM), 22, 23 to yield fractional plasma volume (v p ) and other physiological parameters such as the transfer constant K trans . Figure 1c shows representative CBF ACcomb images of a patient with NF2 alongside maps of v p and K trans derived using the LDHT and FDHS acquisitions of the ICR-DICE. 14 As can be seen from Figure 1c , the LDHT derived K trans map is free from vessel artifacts, whereas the K trans map derived from the FDHS showed greater tumor heterogeneity detail thanks to the higher spatial resolution but at the expense of vessel artifacts due to overestimation of K trans in areas of high v p resulting from the low temporal resolution (Dt 5 10 s). For direct comparison between various parametric matrices, a data processing pipeline was constructed using SPM scripts 16 to allow intra-subject spatial alignment between various MR images and derived parametric maps. Segmented tissue masks (WM, GM, CSF, and tumor, respectively) were then applied onto parametric maps for generating region of interest (ROI) mean values, or for pixel-by-pixel comparison between multi-parametric maps. For repeated studies, longitudinal spatial alignment was also performed using the ending frame, i.e., the last 3D volume of the LDHT or FDHS DCE series acquired on day 0 as the destiny of the coregistration for all other images of the patient at day 0 or day 90. The comprehensive image spatial alignment between the T2*W-DSC and T1W-DCE images facilitated more convenient visual inspection and pixel-by-pixel comparison of T2*W-CBF and T1W-CBF ET maps.
Statistical Analysis
The accuracy and precision of the five methods were compared by Monte Carlo simulation of the mean and SD of percent deviations for CBF estimates at varying levels of Rician noise. Using the LDHT T1W DCE and T2*W DSC-MRI data from the patient with a GBM, we investigated the concordance in the relationships of T2*W-CBF versus T2*W-CBV and T1W-CBF ACcomb versus v p in tumor on a pixel-by-pixel basis. Pixel scatter plots and linear regression analysis were further used to assess concordance of intratumoral T1W-CBF ET and T2*W-CBF estimates and to assess the intratumoral pixelwise relationship of T2*W-CBF compared with T2*W-CBV, and T1W-CBF ACcomb compared with v p . Pixelwise concordance between the derived T1W(SVD)-CBF estimates and T1W-CBF ET and T2*W-CBF data is shown in supplementary data, which is available online.
To assess the reproducibility of the ACcomb method, mean GM and WM CBF values were calculated from each MRI scan, for the 7 sporadic VS patients who underwent two consecutive DCE-MRI acquisitions. The reproducibility of each pairwise comparison was then assessed using the test-retest coefficient of variation (CoV). For each subject, i, the CoV is the SD, r i , for the two measurements on that subject, divided by the mean, l i , for the subject. The overall test-retest CoV for a group of N subjects is then 24, 25 :
To compare the pre-and posttreatment values of CBF in patients with NF2, the average CBF values of GM, WM, and tumor (VS) over the whole-volume ROIs were calculated for each visit of each patient, using the five T1W-ET methods, respectively. A paired ttest was used to compare the group mean values on day 0 and day 90. To reduce the potential for Type I errors through multiple comparisons using the five T1W-ET methods, the standard significance level of P 5 0.05 was adjusted using the Bonferroni correction (C 5 5) to achieve a family-wise error rate (FEWR) of no more than 5%.
Results
VIF and the Tissue Concentration Curves Within the ETW (Hypothesis 1) From the LDHT T1W-DCE MRI Fulfills the Requirements of the Microsphere Model Figure 2 shows variation in the shape of C b (t) curves measured from the SSS of different individuals, when using the power injector with the same GBCA dose and injection rate. Of the 55 MRI exams studied, 92.7% had either 5 (43.6%), 6 (38.2%), or 7 (10.9%) data points on the upslope segment before the first pass peak of the measured C b (t) curves. For a study using the microsphere model, the validity of the technical acquisition needs to be checked by ensuring that the integrated input curve, multiplied by the tissue blood flow, parallels to that of the tissue time-density curve, thus fulfilling one of the requirements of the model. [1] [2] [3] Figures 3a and 3b demonstrate an example of this. INT aif was calculated by integration of the gamma variant fit of the C b (t); the measured WM and GM curves were AC-time curves from the whole-volume ROIs, which were automatically defined from the WM and GM masks, respectively. In Figure 3a , the INT aif was time-shifted and scaled to align with the rising bolus time course of the WM concentration curve, resulting in a calculated f wm of 25 mL/min/100 mL. In Figure 3b , the INT aif was time-shifted and scaled to align with the rising bolus time course of the GM concentration curve, resulting in a calculated f gm of 60 mL/min/ 100 mL. Figures 3c and 3d show a simulation of the tissue concentration curves based on the microsphere model. The flow-scaled INT aif and ROI-averaged WM and GM concentration curves used in the simulation were the same as in Figures 3a and 3b . The upslope part of the theoretical tissue curve (the working data range, ETW, for CBF measurement) was sampled from the flow-scaled INT aif , while keeping the downslope part, starting from and including the tissue peak time point, of the measured tissue curve. Figure 4 compares percent deviation (mean and SD) in CBF WM and CBF GM derived from ACrMG, ACrPK, ACcomb, upslope, and the traditional MG methods, using various noise levels. The traditional MG method yielded poor accuracy and precision even at small noise levels for simulated WM and GM curves. The upslope method showed better accuracy and precision than the MG method but poorer precision than the AC methods, especially at noise levels higher than 3%. For noise levels higher than 2%, the CBF WM estimates obtained from the ACrMG and the ACrPK methods behaved oppositely: the ACrMG analysis (green line) overestimates while the ACrPK (blue line) underestimates CBF WM . The ACcomb method, which is the average of the ACrMG and ACrPK values, estimates CBF WM more accurately, and reduces the SD of PD in CBF WM estimation (Figs. 4a,c) . The CBF GM estimates (Figs. 4b,d) , showed much less variation in the three AC methods, which may be due to the more than twofold greater ENR in the GM uptake curves relative to the WM curves for the same noise level. The overall performance of the ACcomb method was better than the other two AC methods (ACrMG and ACrPK) at a noise level of 4% or higher, but consistently underestimated CBF GM by approximately 5%. For noise levels < 4%, the accuracy of CBF ACrPK became close to, or better than that of CBF ACcomb . Furthermore, comparing Figure 4a with 4b revealed that CBF GM /CBF WM obtained by ACcomb would be on average around 5% lower than the "true" CBF GM /CBF WM , while CBF GM /CBF WM obtained by ACrPK would be on average [2%, 5%, 11%, 14%, 15%] higher than the "true" CBF GM /CBF WM with the error increasing with increasing noise level (0.01, 0.02, 0.03, 0.04, 0.05, respectively). This was because, although ACrPK underestimated both CBF GM and CBF WM , the size of the negative PD of CBF WM was larger than that of CBF GM .
AC Methods Performed Better Than Upslope or Maximum Gradient Methods on Monte Carlo Simulations
Noise Levels for the In Vivo Pixel SI Curves Are Consistent With the Noise Levels Used in the Simulation Figure 5 shows in vivo SI curves for GM and WM derived from individual voxels (Figs. 5a,b) and ROIs placed within the GM and WM, respectively (see Figs. 5d,e), whereas Figure 5f shows the vascular input function. The SI baseline mean, SD, noise level ( 5 SI baseline SD/mean), ENR and the estimated CBF values are shown on the panel for each of the tissue pixel/ROI SI curves. As can be seen, the noise levels for the pixel SI curves acquired from a 1.5T scanner show around 4% or less, consistent with the noise levels used in the simulation. Figure 6a shows the CBF images derived using the LDHT T1W DCE-MRI (the left five columns) and the T2*W DSC-MRI (the right column) acquired at 3T from a patient with a right-sided GBM. The left hand panel shows representative axial section taken from the acquired whole brain 3D CBF ACcomb images. Using the ACcomb method, the calculated mean CBF value was 75.3 mL/min/100 mL for GM and 32.3 mL/ min/100 mL for WM, giving a CBF GM /CBF WM ratio of 2.33. The derived CBF maps using the ACrMG and ACrPK methods are visually similar to the ACcomb method, but as shown in Figure 6a there is over-estimation of the mean CBF values of GM and WM when using the classical MG and the upslope methods. The mean ROI CBF values of the GM, WM, and tumor derived from the five methods are listed in Table 1 . Spatial alignment of the T2*W DSC-MRI to their T1W counterparts (see Fig. 6a ), showed expected differences in appearances of the vasculature within both the "normal" brain and the tumor itself due to the susceptibility effects of intravascular contrast in T2*W images. The mean values of the T2*W-CBF and those of T1W-CBF ET derived by the 
AC Methods Provide More Accurate Estimation of In Vivo CBF Values Than Classical Maximum Gradient (MG)/Upslope Methods
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AC-based methods for both GM and WM are globally compatible, however, as shown in Table 1 . 
CBF Estimation Using T1W(SVD) Approach
Overestimates Tumor CBF As can be seen in Table 1 , when using an ROI analysis with parametric maps, T1W (SVD) methods gave mean CBF values for WM and GM compatible with the T2*W-SVD and our T1W-CBF-ET method, but overestimated CBF in the tumor itself. Our pixelwise analysis is shown in supplementary data, and showed a close pixelwise correlation between the T1W(SVD) T1W-CBF ACcomb estimates for both GM and WM. Figure 7 shows CBF (top row) maps derived from a NF2 patient with a large left-sided VS and four meningiomas. The v p images derived using the ETM are also displayed for comparison in the bottom row. Slices from three levels of the 3D parametric images are shown. As can be seen there is some reduction of CBF and v p within the VS at 90 days and the appearances of the T1W-CBF ACcomb maps and v p maps are very similar at each time-point. Table 3 lists the group mean values ( 6 SD) of CBF for GM, WM, and CBF GM /CBF WM , respectively, for the 12 patients with NF2 treated with bevacizumab. Estimated mean values on day 0 and day 90 using the five different ET methods are listed. The ACcomb produced mean CBF GM of 55.9 6 13.9 mL/100 g/min. CBF WM of 25.8 6 3.45 mL/100 g/min on day 0, CBF GM of 61.0 6 8.28 mL/100 g/min. CBF WM of 28.4 6 3.43 mL/100 g/min on day 90. The ACcomb and ACrPK methods produced the highest CBF GM /CBF WM ratios (2.15-2.34), and the least intra-group SD for GM (8.04-13.92), and WM (3.06-3.45), respectively. With a paired t-test, both the AC-based methods ACcomb and ACrPK show a moderate increase in the group mean value of CBF in NAWM after treatment (Adjusted P values 0.03 and 0.005, respectively). Of interest, neither the classical MG nor upslope method, show such changes in WM and GM CBF after treatment.
Good Reproducibility of the ACcomb Method Reported in Terms of CoVs
Discussion
We present a new method based on the microsphere principle, for estimation of absolute CBF using a low-dose high temporal T1W DCE MRI acquisition. This new method allows a more accurate and reliable estimation of absolute CBF, as instead of using a conventional MG-based algorithm, an averaged CA concentration-based method is used, which uses data points located in a higher ENR segment of the rising bolus time course.
Monte Carlo simulations demonstrated that these ACbased T1W-CBF ET methods provided more accurate estimates of CBF compared with the MG and slope methods, especially when the ENR is low, such as within NAWM. The mean CBF of GM was, however, underestimated when using the ACrPK and ACcomb methods. The observed 5% underestimation in CBF GM values using this new combined method is, however, in alignment with published simulation results, such as those of Wu et al using deconvolution, 26 and those of Kwong et al using the ET in DSC MRI. 7 In vivo evaluation of this new T1W-CBF ET algorithm in 20 patients showed that the MG method produced the poorest CBF estimates (CBF GM /CBF WM ratio less than 1.5), whereas the ACcomb and ACrPK methods produced a more reasonable CBF GM /CBF WM ratio (average 2.15-2.52). The CBF WM calculated by ACrPK was lower than that produced by ACcomb; and the CBF GM calculated by ACrPK was lower than that by ACcomb for DCE MRI 1.5T data, but higher than that by ACcomb for DCE MRI for 3T data. The CBF GM /CBF WM ratio produced by ACrPK (2.52 and 2.30 for 3.0T and 1.5T data, respectively) was higher Mean CBF values were calculated using ROIs at 1.5 T scanner.
Journal of Magnetic Resonance Imaging
than that from ACcomb (2.33 and 2.15 for 3.0T and 1.5T data, respectively). These in vivo observations were consistent with the Monte Carlo simulations, and can be attributed to the lower ENR on 1.5T compared with 3.0T.
13
A correlation between CBF and CBV in both normal brain tissue 21, 27 and gliomas 28 has been previously reported using both a simple linear model and the Grubb formula. 29 In our study, we compared the relationships between T2*W-CBF and T2*W-CBV and between T1W-CBF ACcomb and v p on a pixel-by-pixel basis within a high grade glioma. Both pairs were highly correlated, consistent with previous results. 28 On the other hand, there was a weak pixel wise correlation between the ET derived T1W-CBF and deconvolution derived T2*W-CBF maps. This discrepancy may be due in part to the fundamental differences in mechanism between T1 relaxivity and T2* susceptibility contrast effects. 30 Alternatively, image distortion due to magnetic susceptibility effects, especially when using fast T2*W-DSC imaging techniques may limit accurate coregistration of T1W-DCE and T2*W-DSC images thereby adversely affecting pixelwise correlations. [31] [32] [33] Indeed, the relatively good concordance between AC-based T1W-CBF ET and deconvolution derived T2*W-CBF values when using an ROI analysis suggests that this may be the case. In addition to providing more accurate reliable estimates of CBF, the reproducibility of this new AC-based method was established by test re-test analysis. The overall CoV for absolute CBF measured using the ACcomb method compared favorably with a recent study using both H 2 O 15 PET and contrast-enhanced perfusion. 34 Some authors have advocated the use of model free singular value decomposition approaches for CBF derivation from DCE-MRI data. There are, however, distinct advantages to the use of ET methods over SVD approaches. First, T1W(SVD) cannot distinguish signal contributions from intra-and extra-vascular space, and is, thereby, more affected by vessel leakage than the CBF-ET methods. In our study, SVD methods applied to T1 data gave mean CBF values for WM and GM comparable to those acquired with T2*W-SVD and T1W-CBF-ET method. However, in tumors, there was overestimation of CBF, an effect we hypothesize is due to blood-brain barrier breakdown and contrast leakage.
In addition, perfusion calculation by deconvolution is critically dependent on the data ENR. 7 In the work by Larsson et al, 13 T1W-DCE MRI data was acquired on a 3T
scanner with a GBCA dose of 0.05 mmol/kg to ensure sufficient ENR for pixelwise calculation of CBF using Tikhonov's procedure of deconvolution. Despite this, the authors commented that the relatively poor ENR at 1.5T prevented the calculation of CBF maps using the deconvolution approach. 35 Through using data points located in a higher ENR segment of the rising bolus time course, however, our ET methods suffer less from this limitation. The CBF increases demonstrated using the ACcomb and ACrPK method in normal appearing WM (NAWM) at 90 days post bevacizumab treatment were statistically significant, and exceeded our demonstrated reproducibility threshold for WM CBF measurements. This suggests that these changes are genuine rather than due to reproducibility FIGURE 7: T1W-CBF ACcomb (top row) and v p maps (bottom row) derived using the extended Tofts model in an NF2 patient with a large left-sided VS and multiple meningiomas. These maps were derived from the low-dose T1W DCE-MRI acquired on a 1.5T scanner, pre-and 90 days post bevacizumab therapy. Slices from three levels of the 3D maps of CBF and vp are displayed, which show: a VS within the left cerebellopontine angle (left two columns, white arrow); a representative slice at the level of the centrum semiovale (middle two columns); and a right-sided occipitoparietal meningioma (right two columns, white arrow).
variation, and, whilst this is a preliminary study of only 12 patients, these findings are biologically plausible, as the therapeutic effect of bevacizumab in this group is believed to result from alleviation of intracranial pressure due to reduction in intratumoral edema. 36 Larger studies will, however, be needed, to further investigate bevacizumab treatment related changes in microcirculatory parameters of normal-appearing brain tissues. The key advantages of our new AC-based T1W-ET methods can be outlined as follows: (i) Application of T1W-ET in leaky tissue. The T1W-ET method is less vulnerable to confounding resulting from leakage, re-circulation, and back flux. 7, 11 (ii) Improved robustness to low signal-to-noise ratio. Through use of data points located in a higher ENR segment of the rising bolus time course, the AC-based T1W-ET method allows pixel-by-pixel calculation of CBF using T1W-DCE MRI acquired at both 1.5T and 3T scanners, with a GBCA dose as low as 0.02 mmol/kg. (iii) Simplified data processing. When using the AC-based T1W-ET methodology there is no need to measure TOA, de-noise data, or correct for leakage and re-circulation. (iv) Acquiring 3D DCE-MRI covering the whole brain. A time resolution of 1 s was chosen in this study, allowing averaging of three GBCA concentration data points when using the new T1W-ET methods, whilst permitting acquisition of 3D DCE images covering the whole brain. (v) No covariance error due to multi-parameter fitting procedure. Calculation of CBF with ACcomb does not require multi-parametric fitting, which is prone to covariance errors and "salt-andpepper" noise. 37 The generation of CBF ACcomb maps does not require filtering, in contrast to the maps generated using the two-compartment exchange model. 37 Finally, one important advantage of the new method is that it allows a lower dose of GBCA to be used compared with other methods of determining CBF such as DSC-MRI. To successfully use the microsphere model in determining CBF, a low-dose compact contrast bolus injection is optimum to ensure there is no efflux of intravascular tracer before the first pass AIF peak and to enable better determination of the arterial input function peak. 20 Reduced contrast dose is a pertinent clinical concern, as the potential nephrotoxicity of full dose GBCA is well recognized, 38 and there is growing evidence that gadolinium deposition may occur in the brain following repeated exposures. 39, 40 Patients with CNS tumors, especially more benign lesions, may receive many contrast enhanced MR scans throughout their lifetime. As such, an MR acquisition method, which permits derivation of accurate perfusion metrics using a lower dose of CA, may be of high clinical utility. There are some limitations in our study. First, the new AC-based methods for CBF measurements were evaluated in only a small cohort of patients with intracranial tumors. Second, the 3D whole brain acquisition used in the study comes at the expense of lower spatial resolution than methods used by other authors, who acquired only 4-10 slices. 7, 21, 37 Finally, a uniform value of hematocrit was used in this study, despite expected inhomogeneities in intra-and inter-subject hematocrit. Because measurements of regional cerebral blood flow are dependent upon regional hematocrit, any alteration in this may produce errors in the calculation of regional blood flow.
In conclusion, we have developed and assessed a new ET method of estimating absolute CBF using LDHT DCE MRI data. Monte Carlo analysis shows that this new method improves the accuracy of measured absolute CBF values at different noise levels. In vivo application of this new method showed that the acquired T1-CBF ET maps displayed excellent GM-WM flow contrast using a much smaller dose of GBCA than is used for conventional DSC experiments, and the measured values of WM and GM CBF using our new method matched perfusion values in literature. The typical test-retest CoV observed in this study suggest that T1W-ET measured CBF have sufficient reproducibility to be used in longitudinal studies, especially if large changes due to therapeutic intervention are expected, In a cohort of patients with NF2 undergoing treatment with bevacizumab, there was a moderate increase in CBF of NAWM 90 days posttherapy. Our new method offers advantages over currently used noninvasive methods of CBF measurement, and may have considerable future utility in clinical perfusion imaging.
